TY - JOUR
T1 - Macrophages as regulators of tumour immunity and immunotherapy
AU - DeNardo, David G.
AU - Ruffell, Brian
N1 - Funding Information:
The laboratory of D.G.D. is supported by funding from the National Cancer Institute, including P50CA196510, R01CA177670, R01CA203890 and P30CA091842 Supplement-15S3, as well as The Mary Kay Foundation. The laboratory of B.R. is supported by funding from the National Institutes of Health (R00CA185325), the Florida Department of Health Bankhead-Coley Cancer Research Program (8BC02) and the Florida Breast Cancer Foundation. The authors thank members of their laboratories for helpful discussion.
Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Macrophages are critical mediators of tissue homeostasis, with tumours distorting this proclivity to stimulate proliferation, angiogenesis and metastasis. This had led to an interest in targeting macrophages in cancer, and preclinical studies have demonstrated efficacy across therapeutic modalities and tumour types. Much of the observed efficacy can be traced to the suppressive capacity of macrophages, driven by microenvironmental cues such as hypoxia and fibrosis. As a result, tumour macrophages display an ability to suppress T cell recruitment and function as well as to regulate other aspects of tumour immunity. With the increasing impact of cancer immunotherapy, macrophage targeting is now being evaluated in this context. Here, we discuss the results of clinical trials and the future of combinatorial immunotherapy.
AB - Macrophages are critical mediators of tissue homeostasis, with tumours distorting this proclivity to stimulate proliferation, angiogenesis and metastasis. This had led to an interest in targeting macrophages in cancer, and preclinical studies have demonstrated efficacy across therapeutic modalities and tumour types. Much of the observed efficacy can be traced to the suppressive capacity of macrophages, driven by microenvironmental cues such as hypoxia and fibrosis. As a result, tumour macrophages display an ability to suppress T cell recruitment and function as well as to regulate other aspects of tumour immunity. With the increasing impact of cancer immunotherapy, macrophage targeting is now being evaluated in this context. Here, we discuss the results of clinical trials and the future of combinatorial immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85061211313&partnerID=8YFLogxK
U2 - 10.1038/s41577-019-0127-6
DO - 10.1038/s41577-019-0127-6
M3 - Review article
C2 - 30718830
AN - SCOPUS:85061211313
SN - 1474-1733
VL - 19
SP - 369
EP - 382
JO - Nature Reviews Immunology
JF - Nature Reviews Immunology
IS - 6
ER -